Pliant Therapeutics
PLRX
55 hedge funds and large institutions have $636M invested in Pliant Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 11 closing their positions.
164% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 11
49% more funds holding
Funds holding: 37 → 55 (+18)
0.14% less ownership
Funds ownership: 79.7% → 79.56% (-0.14%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $877M → $636M (-$242M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.4M |
| 2 |
BlackRock
New York
|
+$9.97M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.84M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$3.8M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.99M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$3.07M |
| 3 |
ZP
Zimmer Partners
New York
|
-$2.78M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$2.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.16M |
PLRX Hedge Fund Activity: Q3 2020 in Review
55 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2020, worth a combined $636M — down 28% from $877M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PLRX positions and 11 closed out — a net gain of 18 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $10.4M. The largest seller was Logos Global Management, cutting an estimated $7.99M.
- 55 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2020, up from 37 in Q2 2020.
- Funds reported $636M of Pliant Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
- 29 funds opened new Pliant Therapeutics positions in Q3 2020 and 11 closed out, a net change of +18 holders.
- The largest Pliant Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $10.4M added.
- The largest Pliant Therapeutics seller in Q3 2020 was Logos Global Management, an estimated $7.99M sold.
Based on aggregated 13F filings for Q3 2020.